### Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

#### PROGENICS PHARMACEUTICALS INC

Form 8-K May 28, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 27, 2015

Progenics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware 000-23143 13-3379479 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)

777 Old Saw Mill River Road,

Tarrytown, New York

(Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (914) 789-2800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

Item 8.01. Other Events.

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) announced that Mark R. Baker, CEO, is scheduled to present at the Jefferies 2015 Healthcare Conference on Wednesday, June 3, 2015, at 11:00 a.m. Eastern Time. The conference is being held at The Grand Hyatt.

A copy of Progenics' press release is included in this Report as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release dated May 27, 2015.

# Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 8-K

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.
By:/s/ ANGELO W. LOVALLO, JR.
Angelo W. Lovallo, Jr.
Vice President - Finance & Treasurer
(Principal Financial and Accounting Officer)

Date: May 28, 2015